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Abstract
Background: The prevalence of smoking is declining; however, it continues to be a major public health burden. In England,
primary care is the health setting that provides smoking cessation support to most smokers. However, this setting has one of the
lowest success rates. The iQuit in practice intervention (iQuit) is a tailored web-based and text message intervention developed
for use in primary care consultations as an adjunct to routine smoking cessation support with the aim of increasing success rates.
iQuit has demonstrated feasibility, acceptability, and potential effectiveness.
Objective: This definitive trial aims to determine the effectiveness and cost-effectiveness of iQuit when used as an adjunct to
the usual support provided to patients who wish to quit smoking, compared with usual care alone.
Methods: The iQuit in Practice II trial is a two-arm, parallel-group, randomized controlled trial (RCT) with a 1:1 individual
allocation comparing usual care (ie, pharmacotherapy combined with multisession behavioral support)—the control—with usual
care plus iQuit—the intervention. Participants were recruited through primary care clinics and talked to a smoking cessation
advisor. Participants were randomized during the initial consultation, and those allocated to the intervention group received a
tailored advice report and 90 days of text messaging in addition to the standard support provided to all patients.
Results: The primary outcome is self-reported prolonged abstinence biochemically verified using saliva cotinine at 6 months
after the quit date. A sample size of 1700 participants, with 850 per arm, would yield 90% power to detect a 4.3% difference in
validated quit rates between the groups at the two-sided 5% level of significance. The Cambridge East Research Ethics Committee
approved the study in February 2016, and funding for the study was granted from May 2016. In total, 1671 participants were
recruited between August 2016 and July 2019. Follow-up for all participants was completed in January 2020. Data analysis will
begin in the summer of 2020.
Conclusions: iQuit in Practice II is a definitive, pragmatic RCT assessing whether a digital intervention can augment the impact
of routine smoking cessation support in primary care. Previous research has found good acceptability and feasibility for delivering
iQuit among smoking cessation advisors working in primary care. If demonstrated to be cost-effective, iQuit could be delivered
across primary care and other settings, such as community pharmacies. The potential benefit would likely be highest where less
behavioral support is delivered.
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Introduction
Public Health Burden of Smoking
In 2015, the total estimated smoking-related cost to the UK
National Health Service (NHS) was GB £2.6 billion (US $3.3
billion), of which GB £1.1 billion (US $1.4 billion) was within
primary care settings [1]. Smoking-related morbidity accounts
for 489 300 hospital admissions and 77,800 deaths in England
each year. About 14.4% of adults in England currently smoke
[2], and despite the fact that smoking prevalence has fallen over
recent years, this equates to approximately 6.4 million adults
aged >20 years [3]. Prevalence has reduced mostly in the 18-
to 24-year age group; however, the proportion of adults still
smoking is highest among the unemployed and those of a lower
economic status. There has been some improvement in the quit
success rate of this population, which may be due to the
European Union tobacco products directive, which was finalized
in 2017 [4]. Prohibition of smoking in public spaces and the
use of smoking cessation services may have contributed to the
reduction in smoking prevalence over the last 15 years [5].
However, to achieve the Department of Health’s vision of a
smoke-free generation by 2035 [6], there is a strong need to
increase the effectiveness and cost-effectiveness of existing
interventions embedded within health care in addition to other
tobacco control initiatives.
Primary Care as a Setting for Smoking Interventions
Since 2012, when revisions were made to the quality and
outcomes framework’s reporting of smoking status, general
practitioners (GPs) have been incentivized to offer and record
stop-smoking support to all registered patients [7]. Therefore,
primary care is an important setting for smoking cessation
support. Physicians, nurses, and other health care practitioners
are in a prime position to engage with and provide smoking
cessation support to patients presenting at specialized health
clinics (eg, asthma, hypertension, diabetes) and general
consultations. Many practices train at least one health care
practitioner to offer and deliver smoking cessation support, and
the two most commonly trained practitioners to deliver support
(ie, health care assistants and nurses) are equally effective at
delivering this support [8].
The stop smoking services (SSS) follow the National Institute
for Health and Care Excellence recommendations [9] to provide
one-to-one behavioral support, discussing and providing
pharmacotherapy for smokers wishing to quit. Although the
number of people attending NHS stop smoking services in
primary care and general practice has fallen in recent years
[2,10], the proportion of successful quit attempts (self-report at
4 weeks after a quit attempt) remains steady at 51% [10]. A
systematic review of 44 studies showed that patients receiving
cessation support from nurses or other health care practitioners
offering advice, counseling, and other strategies increased their
chances of a successful quit attempt (at 6 months after quit date)
by 29% (relative risk [RR] 1.29; 95% CI 1.21 to 1.38), 15.7%
in the treatment arm (nursing intervention) versus 12.2% in the
control arm (minimal intervention) [11]. In this review, nursing
intervention was defined as the provision of any kind of support
or advice by nurses, and the control group comprised those who
saw the same nurse but received only brief advice and self-help
materials. In addition, increasing the amount of behavioral
support can further aid the smoker to quit (RR 1.15; 95% CI
1.08 to 1.22) [12].
Text Messaging and Tailored Interventions for
Smoking Cessation (Effectiveness and
Cost-Effectiveness)
Tailored interventions use data collected on or about an
individual to make the information provided to them more
personally relevant, increasing the likelihood that it will be read,
understood, and acted upon. Tailored self-help interventions
can be more effective than nontailored materials (RR 1.28; 95%
CI 1.18 to 1.37) [13] and are better than no help at all (RR 1.34;
95% CI 1.19 to 1.51) [13]. In addition, text messaging programs
can increase quit rates (RR 1.54; 95% CI 1.19 to 2.00) [14].
Currently, 96% of adults in the United Kingdom have access
to a mobile phone, and in 2017, 6.4 billion SMS text messages
were sent [15]. A Cochrane review of 12 studies assessing the
effectiveness of text-based mobile phone interventions to support
a quit attempt found a positive effect of mobile phone
interventions on abstinence compared with controls at 6 months
(RR 1.67; 95% CI 1.46 to 1.90), 9.3% in the treatment arm
versus 5.6% in the control arm [16]. The majority of
interventions in these trials were SMS text message based,
whereas the control arms varied from daily nontailored text
messages to no intervention.
The York Health Economics Consortium [17] concluded that
there was not enough evidence concerning the cost-effectiveness
of NHS-related smoking interventions. Their review showed
some cost benefits, but the studies analyzed were far-reaching
and included smoking cessation support in hospital settings,
some very old studies, and studies that were of both low- and
high-intensity interventions.
However, smoking cessation interventions have been shown to
be cost-effective in many populations, including low-income
populations [18] and people with chronic obstructive pulmonary
disease (COPD) [19]. Tailored smoking cessation interventions
have also been shown to be cost-effective [20], with the cost
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benefit increasing the older the smoker is at the time of quitting
(Table 1—data adapted from the txt2stop trial) [20]. However,
although quitters in the txt2Stop trial had access to NHS SSS,
the intervention was delivered as an adjunct to these services
and not through them.
Table 1. A summary of incremental costs and quality-adjusted life years gained per 1000 participants.
Age (years)Characteristics
>4030-40<30
−74,214 (−91,756)−30,320 (−37,487)−11,066 (−13,682)Incremental cost, GB£ (US$)
382720Incremental quality-adjusted life years
The intervention in this trial (iQuit in practice intervention
[iQuit]) is a tailored smoking cessation system designed for use
by health care practitioners during the delivery of routine
cessation support. iQuit is the culmination of research into the
effectiveness of tailored smoking cessation advice reports
[21-24] and evidence from trials using SMS text messages as
a means of delivering tailored messages to smokers to assist
them in their quit attempt [20,25-31]. Using a web-based
questionnaire, the practitioner asks smokers a series of questions
that are used to tailor an advice report. iQuit also delivers a
90-day program of automated, tailored, and interactive text
messages, designed to support the smoker in their quit attempt.
The iQuit in Practice Pilot Trial
iQuit has previously been assessed for feasibility, acceptability,
and short-term effectiveness in a randomized controlled trial
(RCT) [32]. In the trial, we found good acceptability for iQuit
from participants and advisors. A total of 93.7% of participants
found the texts easy to understand, 67.7% felt receiving support
by text message acceptable, and 44.8% said that the text
messages had helped them to quit smoking. It took advisors
approximately 8 min (mean 7.7 min SD 4.0) to deliver the
intervention and gave a mean score of 4.6 (SD 0.7, 5-point scale)
for ease of using the web-based questionnaire within a
consultation [32]. In terms of its effect on short-term abstinence
(Table 2), the primary focus of the trial, we found no significant
between-group differences. However, although not prespecified,
we found statistically significant between-group differences for
both self-reported 6-month prolonged abstinence at the 6-month
follow-up and for continuous abstinence.
Table 2. Summary of smoking outcomes from the iQuit in Practice pilot trial.
Odds ratio
(95% CI)
Absolute difference, %
(95% CI)
Intervention
arm, n (%)
Control
arm, n (%)
Smoking outcomes for the iQuit in Practice pilot trial
Primary outcome
1.22 (0.88 to
1.69)
4.9 (−3.0 to 12.7)135 (45.2)122 (40.3)Self-reported 2-week point-prevalence abstinence at 8-week follow-
up
Secondary outcomes
1.21 (0.84 to
1.76)
3.7 (−3.3 to 10.6)81 (27)71 (23)Carbon monoxide–verified 2-week point-prevalence abstinence at 4-
week follow-up after quit date
1.13 (0.78 to
1.65)
2.3 (−4.5 to 9.1)76 (25)70 (23)Self-reported 3-month prolonged abstinence at 6-month follow-up
Additional outcomes
1.81 (1.09 to
3.01)
6.1 (0.9 to 11.4)45 (15)27 (9)Self-reported 6-month prolonged abstinence at 6-month follow-up
1.92 (1.07 to
3.45)
5.1 (0.6 to 9.8)34 (11)19 (6)Continuous abstinence (4-week, 8-week, and 6-month follow-ups)
The RR for the long-term intervention effect at 6 months was
1.69 (95% CI 1.08 to 2.65). The estimated probability that the
intervention would produce a small intervention effect
equivalent to an RR of at least 1.2 is 93%, and the probability
of a medium effect size of 1.5 is 70%.
This trial is therefore a definitive, pragmatic RCT in primary
care to assess the effectiveness and cost-effectiveness of iQuit
on biochemically validated abstinence at a 6-month follow-up.
It will be assessed against the usual practice for smoking
cessation consultations.
Trial Objectives
The study aims to assess the effectiveness and cost-effectiveness
of iQuit when delivered alongside usual care compared with
usual care alone.
Design
iQuit in Practice II is a two-arm, parallel-group RCT with 1:1
individual allocation comparing usual care (control) with usual
care plus iQuit (intervention).
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Methods
Practices: Recruitment
Participants were recruited from general practices in the East
of England under the remit of the Eastern and North Thames
clinical research networks. Our pilot study [32] suggested that
22 is a feasible minimum target of participating smokers per
practice; therefore, we set out to approach 66 practices over 36
months to achieve our initial proposed sample size of 1452
participants. However, participant recruitment was monitored
and reported monthly to the study team by the trial coordinator.
Detailed graphs and charts of overall and per practice activity
informed whether more or fewer general practices were needed
to achieve the target.
General practices were eligible if they had at least one smoking
cessation advisor trained to deliver level 2 smoking cessation
advice (or were willing to be trained to that level). Practices
were not to be participating in any other smoking cessation
research studies, and all smoking cessation advisors had to have
internet access from a computer in their consultation room and
access to a printer. Training and site initiation took place in a
single 2-hour session. Training included informed consent, using
the iQuit web-based questionnaire, and an explanation of RCTs.
Participants: Inclusion and Exclusion Criteria
Patients were eligible for the study if they met all of the
following criteria: (1) a current tobacco smoker (ie, they usually
smoked at least one cigarette a day and had smoked in the past
7 days), (2) able to read and understand English and could
provide written informed consent, (3) ≥18 years, (4) had a
mobile phone and were familiar with sending and receiving text
messages, (5) willing to participate in the study and follow study
procedures, and (6) not enrolled in another formal smoking
cessation study or treatment program at the time.
Health care practitioners were prompted to check whether
patients met the eligibility criteria when they signed on to the
iQuit in Practice computer program. The ability to read and
understand English was a subjective decision by the practitioner
based on their knowledge of the patient and the patient’s medical
records.
Patients were excluded if they were considered by their GP to
be unsuitable for the study for any reason. There was no
proforma of ineligible conditions. It was at the discretion of the
GP and health care practitioner to decide whether or not the
patient should take part in the study. GPs were asked to screen
lists of known smokers before invitation letters were sent.
Reasons for noninclusion included mental illness, terminal
illness, or dementia. Patients with existing medical conditions
such as COPD or heart disease were not excluded unless their
GP considered them unsuitable. As individual allocation worked
effectively in the pilot trial, with no contamination found [32],
patients were also not excluded if more than one person per
household was participating in the trial.
Participants were not re-enrolled into the trial if they had not
been successful in their quit attempt. However, this did not
exclude them from receiving further support from their smoking
cessation advisor.
Participants: Recruitment
Participants were recruited using 3 methods (Figure 1 shows
the projected trial profile):
1. Opportunistic recruitment: All health care practitioners in
participating practices were encouraged to identify potential
participants. Smokers presenting at other clinics (eg, health
checks, asthma clinics, COPD clinics) and expressing a
desire to quit smoking were advised to make an appointment
with the smoking cessation advisor.
2. Self-referral: Patients could refer themselves for smoking
cessation support.
3. Proactive recruitment: Practices were encouraged to mail
study invitations to smokers identified from their database.
In addition to a covering letter, patients received an
information sheet and were encouraged to make an
appointment with the smoking cessation advisor at the
surgery.
Participant recruitment in GP practices was monitored (as
previously described), and a number of strategies were used to
ensure the sample size was achieved (eg, regular newsletters
[sometimes tailored to the practice]). Further support and
training for underperforming practices was available. Practices
were also encouraged to use national promotions (eg, Stoptober
and national no smoking day) to encourage recruitment. Posters
and leaflets were available for practices to display in their
waiting rooms.
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Figure 1. Projected trial profile.
Interventions
Control
In-person SSS support, which is mainly delivered one to one,
is usual practice for smoking cessation consultations in primary
care. During the first session, the advisor discusses with the
patient the reasons for why they smoke and why they wish to
quit. They also assess the patient’s level of nicotine dependence
using validated tools such as the Fagerstrom test for nicotine
dependency, the heaviness of smoking index, or the Urge to
Smoke Questionnaire. They discuss past quit attempts and
support the patient to set a quit date. To aid the quit attempt,
patients are offered pharmacotherapy: varenicline, buproprion,
or nicotine replacement therapy (NRT) products (eg, patches,
gum, lozenges, inhalators, mouth, and nasal sprays). The
patient’s expired-air carbon monoxide (CO) level is also
measured using the practice’s own Smokerlyzer. Follow-up
appointments by the smoking cessation advisor are offered at
1, 2, 3, and 4 weeks after the quit date to monitor progress and
to offer advice on handling withdrawal symptoms and difficult
situations, to monitor CO levels, and to ensure that the patient
has an adequate supply of medication [33].
All participants in our trial received this level of support (usual
care).
Intervention
In addition to the usual care described earlier, participants
allocated to the intervention arm received the following.
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Tailored Advice Report
iQuit uses participant answers to the iQuit web-based
questionnaire to instantly generate a highly tailored detailed
advice report (Multimedia Appendix 1), approximately 4 A4
pages in length. The program is informed by (1) theories of
smoking cessation and behavior change, including social
cognitive theory [34] and the perspectives of change model
[35]; (2) findings from previous studies; (3) feedback from the
iQuit in Practice I trial [32]; and (4) best practice guidance from
the National Centre for Smoking Cessation Training [36]. To
ensure adequate tailoring, iQuit asks detailed questions about
an individual’s smoking habits and history, including nicotine
dependence, motivation and determination to quit, reasons for
quitting, self-image, pros and cons of quitting, perceived difficult
situations, children, living with other smokers, social support,
and current health problems. The advice report contains detailed
advice on quitting tailored to 25 items from the web-based
questionnaire. The program can generate over 3300 million
different reports.
Tailored Text Messages
A 90-day program of automatically generated tailored text
messages (Multimedia Appendix 2) is sent to the participant’s
mobile phone, beginning the day before their quit date.
Participants receive either 0, 1, or 2 messages each day
(approximately 1.2 on average), with fewer messages toward
the end of the 90 days. The messages are a further refinement
of those developed for the version evaluated in the first trial
with some additional features [32]. Texts were amended to
reflect the current trend in SMS messaging (eg, the return of
full length rather than abbreviated words, ie, text instead of txt).
However, content, style, and frequency remained unchanged,
as 64.1% of participants in the pilot trial found them useful and
93.7% of participants found them easy to understand. The texts
are designed to remind participants about their quit attempt,
provide information about reasons for quitting, increase and
maintain motivation, boost confidence at quitting, and provide
coping strategies for difficult situations. Messages are
individually tailored using baseline information collected
through the web-based questionnaire with additional information
obtained via interactive messages sent to participants at 4, 5,
and 8 weeks during the program. The 4- and 8-week messages
ask about current smoking status (ie, have they smoked in the
last week. Participants respond by texting Y or Yes, N or No and
those that have smoked in the last week are invited to text in a
new quit date). The 5-week message asks participants about
their confidence in quitting for good using a 5-point scale and
provides feedback in response. Participants can text STOP,
email, or telephone the study team at any time to stop receiving
further messages. For added distraction, participants can text
QUIZ to receive a general knowledge quiz question. After
submitting their answer, they receive a text telling them whether
their answer is correct or incorrect. If they do not respond, they
will automatically receive the correct answer after approximately
5 min. Participants can also text HELP if they are tempted to
smoke, or SLIP if they have had a lapse to receive further
support. If participants want to increase or decrease the
frequency of the text messages, they can text MORE or LESS.
Sample Size, Power, and Precision
In the iQuit in Practice I trial, the quit rates (self-reported
prolonged abstinence at 6 months) were 8.9% and 15.1% in the
control and intervention groups, respectively [32]. If we assume
a 90% response rate to biochemical verification and that 90%
of these are confirmed as nonsmokers (as advised by the chair
of the trial steering committee, Dr Jamie Brown from University
College London), this gives the estimated validated quit rates
of 7.1% and 12.1% for control and intervention, respectively.
An absolute increase of 5% quitting would be a worthwhile and
scalable effect for this low-cost intervention. Detecting an effect
of this size with 90% power using a two-sided chi-square test
at the 5% significance level requires 726 participants per arm
(nonresponders at follow-up assumed to be smoking), and 1452
in total.
In the first 12 months of recruitment, the response rate to
biochemical validation was lower than expected. The observed
response rates suggested that we would fall short of the 282
biochemically validated nonsmokers required to maintain 90%
power (column 3 of Table 3 gives further details). On the basis
that, we needed the same number (n=282) of validated
nonsmokers. Using the observed response rates of participants
to biochemical validation (64%), a revised sample size of 1700
participants was proposed. With 850 participants per arm, the
study has 90% power to detect a 4.3% difference in validated
quit rates of 10.3% versus 6.0% at the two-sided 5% level of
significance. The trial steering committee (TSC) and the research
ethics committee approved the revised sample size of 1700
participants.
Table 3. Sample size assumptions.
Scenario 3, nScenario 2, nScenario 1, nRaw numbers
170014521452Sample size
561479348Self-reported abstinence at 6 months postquit date
287307314Response to biochemical validation
287245282Validated nonsmoker
Randomization
Randomization was stratified by smoking cessation advisor, so
that each advisor would see approximately equal numbers of
intervention and control participants. The allocation sequence
is generated by a computer-based random number generator
using random permuted blocks with block sizes of 4 and 6 to
make the sequence difficult to predict, while avoiding a major
imbalance between intervention and control groups if a block
is incomplete at the end of recruitment. The sequence is stored
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on the web server database, accessible only to the data manager
and the chief investigator. Allocation is made after the questions
in part 1 of the web-based iQuit program have been completed.
Procedure: Initial Consultation
At the start of the initial appointment, the smoking cessation
advisor logs onto the web-based iQuit program, talks through
the information sheet (Multimedia Appendix 3) and goes
through the set of 6 eligibility questions with the patient. If
eligible, the advisor obtains written consent (Multimedia
Appendix 4) from the patient following good clinical practice
guidelines [37].
Once informed consent has been obtained, participants complete
a short health utility questionnaire (EQ-5D-5L) [38] in which
they report any problems with mobility, self-care, usual
activities, pain, anxiety, and depression. Following this, the
smoking cessation advisor continues with usual care before
returning to the iQuit program. There are 2 parts to the iQuit
program. Part 1 includes questions on gender, age, cigarette
consumption, the longest period of abstinence, strength of
motivation, and determination to quit smoking. A quit date
(which must be within 2 weeks of the consultation) is also
recorded in this section along with the CO reading taken earlier
in the consultation. It is only after these questions have been
completed that the computer randomly allocates the participant
to either the control or the intervention group (Multimedia
Appendix 5).
For participants allocated to the control group, there are no
further questions. They are reassured that even though they are
in the control group, their contribution to the research study is
still valuable. They are also reminded that the research team
will follow them up in 6 months. The smoking cessation advisor
finishes the appointment in the usual way, making clinical
follow-up appointments with the participant wherever possible.
For participants randomized to the intervention group, there is
a further set of questions (part 2). These questions include the
tailoring questions described in the intervention section earlier.
Finally, the participant’s mobile phone number is entered, and
their preferred way of being referred to in the text messages.
At the end of part 2, the smoking cessation advisor prints the
generated advice report and hands it to the participant to take
away and read. Intervention participants start receiving the
90-day program of text message support beginning the day
before their quit date.
Procedure: Follow-Up
All participants in the control and intervention groups are
followed up 6 months after their initial quit date. The follow-up
comprises 3 parts:
1. A question to ascertain the success of their quit attempt:
Participants are asked to respond to the question “have you
smoked at all since your quit attempt” with either A1, A2,
or A3 meaning that they have had no cigarettes, not more
than five cigarettes in total or smoked more than five
cigarettes in total, respectively.
2. A saliva sample for biochemical validation: Participants
who respond to the first question with A1 or A2 also receive
a saliva sampling kit for biochemical validation (cotinine
and anabasine in saliva are important biomarkers for
determining a participant’s smoking status) [39,40].
3. A more detailed questionnaire (Multimedia Appendix 6)
that participants can complete on the web, on a printed
copy, or over the telephone.
The preferred method for asking about smoking status is
indirectly through either a text message or via email. However,
if neither of these contact details were available, but the
participant had given a landline telephone number, a researcher,
blind to group allocation, called the participant to ask the
question over the phone. Participants who had not provided a
telephone number or an email address were sent the detailed
questionnaire, which included the primary outcome question,
through the post.
Participants who responded to the first question by text or email
were sent a link to complete the questionnaire on the web.
Participants who responded to the question over the telephone
were given the option of completing the questionnaire at that
time, were sent the questionnaire by post, or completed it on
the web. All participants who answered with either A1 or A2
to the initial question were sent a saliva sampling kit through
the post for biochemical validation of their quit attempt.
All participants were followed up with a telephone call (where
possible) if there was a missing follow-up component (ie, the
saliva sample has not been received by the laboratory within
14 days of it being sent and the questionnaire has not been
returned). Where it was not possible to reach the participant
using these methods, a further sample kit and the questionnaire
was sent to the address we held.
If there was no response to any form of communication within
90 days of their quit date, participants were categorized as lost
to follow-up and treated as smokers for the statistical analysis.
Data Collection, Management, and Analysis
All personal data are stored on a secure server within the
University of Cambridge Clinical School computing services.
Access to the trial database is through a 2-factor authentication
system (Signify). All data are anonymized before analysis and
publication.
Baseline data were collected through the iQuit program, and
follow-up data were collected as described earlier. Saliva
samples were sent to ABS laboratories (BioPark). Cotinine
levels of <15 ng/mL suggest abstinence from smoking by the
participant [41]. Cotinine, however, does not distinguish
between nicotine obtained through tobacco smoke and nicotine
obtained through NRT. Therefore, a second assay to measure
anabasine is run if the cotinine concentration is >15 ng/mL.
Data Monitoring
We have not appointed a data monitoring committee as this is
a low-risk trial assessing a behavioral intervention. However,
a TSC has been formed and meets to oversee recruitment and
follow-up and to provide comments and expertise on the
statistical analysis plan and significant protocol changes.
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Results
In February 2016, the Cambridge East Research Ethics and the
Health Research Authority approved the study to begin
recruiting. Funding began in May 2016 and between August
2016 and July 2019, 1671 participants were recruited. Follow-up
was completed by January 2020 and data collection will
commence in the summer of 2020.
The working protocol for the study is version 7, dated March
27, 2018 (Multimedia Appendices 7 and 8)
Outcomes
In line with the Russell Standard, the primary outcome is
self-reported prolonged abstinence over the entire 6-month
follow-up period (allowing for up to five cigarettes in total),
combined with 7-day point prevalence with biochemical
verification at 6 months [40]. In the event that a participant was
unwilling to provide a saliva sample, they could provide a CO
reading instead. CO readings were taken at their physician’s
surgery (Multimedia Appendices 9 and 10).
Secondary outcomes include (1) CO-verified abstinence at the
4-week quit date follow-up for at least 2 weeks, assessed by the
smoking cessation advisor; (2) self-reported prolonged
abstinence over the whole of the 6-month follow-up period
(allowing for up to five cigarettes in total); (3) self-reported
7-day point-prevalence abstinence at the 6-month follow-up;
and (4) cost and utility measures (ie, the time required to
complete the iQuit program and resource use, including use of
cessation medication).
Process measures, all assessed from the follow-up questionnaire
include (1) the number of serious quit attempts lasting ≥24 hours
during the 6-month follow-up period, (2) motivation and
confidence in quitting, (3) use of strategies to help avoid
smoking or lapsing during the 6-month follow-up period, and
(4) (intervention group only) evaluation of the tailored advice
report and text messaging program (eg, how helpful they found
them, how they felt about the number of texts sent).
Statistical Analysis
A detailed statistical analysis plan was completed by the senior
trial statistician dated August 16, 2018, and approved by the
TSC. The final analysis will be performed after all the follow-up
data has been collected; there is no interim analysis. The
statistician will be blind to group allocation until data queries
have been resolved, and the statistical analysis plan has been
followed. The analysis will take an intention-to-treat (ITT)
strategy approach. The ITT population comprises all patients
that have been randomized, regardless of finding any participant
later to have been ineligible or any controls who have mistakenly
received the behavioral intervention, or any intervention arm
participants who had not received the behavioral intervention.
A per-protocol analysis is not planned because the number of
participants not receiving an intervention was very low in our
previous study [32]. The focus will be on reporting 95% CIs
for estimates of effect size. Statistical tests will be two-tailed
and assessed at the 5% significance level. Tests will be used
sparingly and restricted largely to addressing stated hypotheses
as detailed in the statistical analysis plan, so reporting of P
values will be limited.
Primary Effectiveness Analysis
The primary analysis of the primary outcome will involve
obtaining a point estimate of the intervention effect as the
difference in proportions, with 95% CI and the corresponding
P value for the intervention effect from the Pearson chi-square
test. The primary analysis and sensitivity analysis for handling
missing primary outcome data (primarily assuming this as not
abstinent) will together comprise the ITT strategy. The detailed
statistical analysis plan describes the secondary reporting of
relative effects, such as odds ratio and RR, which should be
useful for comparison with other studies and meta-analyses.
The statistical analysis plan describes further methods for this
sensitivity analysis and for exploratory secondary analysis of
the primary outcome, indicated by unexpected covariate
imbalance. The statistical analysis plan provides further
information as to why, a priori, the primary analysis is decided
to be unadjusted for the stratifier (smoking cessation advisor),
given the low numbers of primary outcome events per stratifier
categories.
Subgroup variables that will be examined as potential
moderators of the intervention are medication use (categorized
into NRT or varenicline), nicotine dependence (based on the
heaviness of smoking index, categories of 7+ and <7), and the
Index of Multiple Deprivation (5 quintile-based categories).
The approach to subgroup analysis will involve assessing the
significance of the interaction of a subgroup variable with arm
allocation and summarizing the intervention effect with a 95%
CI within each category of the subgroup variable.
Secondary Effectiveness Analyses
The key secondary effectiveness outcomes are binary, and a
Pearson chi-square test will be used unless assumptions are
unexpectedly contraindicated. Ordinal response outcomes (and
their changes from baseline, where collected) will be evaluated
between arms using methods for continuous outcomes, in
consideration of the large sample size, unless categories are few
and sparse, requiring categorical analysis methods outlined
further in the statistical analysis plan. Where the baseline is
available, analysis of covariance will be used for continuous
outcomes. Alternatively, the Student t test will be used. If there
is evidence of differential variance between arms (eg, Levene
F-ratio), then an alternative test based on an appropriate
modification to fractional degrees of freedom will be reported
if the variance ratio is large enough to materially alter the result
and conclusion.
Economic Analyses
The economic evaluation will estimate the incremental cost per
incremental individual quitting smoking at 6 months (defined
as self-report with biochemical verification: the primary outcome
measure) and per incremental quality-adjusted life year (QALY)
gained over 6 months.
The setting of the study is English primary care (and is assumed
to be generalizable to the United Kingdom as a whole). The
analytic perspective is that of the NHS over a time horizon of
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6 months. No interim analyses are planned. Costs and outcomes
will not be discounted as the follow-up period is less than one
year. Cost items comprise the index consultation with the
smoking cessation advisor (data derived from the iQuit
program), text messages, prescription medications, and other
primary care contacts. QALYs will be calculated from the
EQ-5D-5L using the recommended set of utility weights at the
time of analysis.
Process Evaluation
Many process measures fall into either ordinal or binary
categories. Those considered to be potential mediators include
motivation, confidence in quitting, use of cognitive behavioral
lapse prevention strategies, medication use, and use of additional
NHS cessation support. Process measures that are
intervention-arm-only are also ordinal or binary, and will be
summarized descriptively in terms of averages and percentages,
and include reading advice reports, reading advice texts, finding
them helpful, and viewing messages (annoying versus pleasing).
For continuous process measures, to obtain valid CIs, the
nonparametric bootstrap method will be considered for use
when the distribution is highly skewed, and an absolute
difference presentation and interpretation is important.
For process measures proximal to the behavior, such as
motivation and confidence in quitting, chi-square trend tests for
between-arm evaluation will be reported after assumption
checking.
For measures proximal to the intervention, such as use of
strategies to help avoid smoking or lapsing during the follow-up
period of the individual’s experience in the trial, Pearson
chi-square test, chi-square trend test, Student t test will primarily
be used depending on response distribution and distributional
assumptions, and interpretability of point and ideally interval
estimate provision.
Discussion
The purpose of this trial is to evaluate the effectiveness and
cost-effectiveness of digital adjunctive support to usual smoking
cessation care in primary care. The trial has been designed
following the Standard Protocol Items: Recommendations for
Interventional Trials [42] and Consolidated Standards of
Reporting Trials [43,44] guidelines (Multimedia Appendix 11),
and feedback from the pilot trial [32] to maximize both internal
and external validities.
Trial Design
A cluster-randomized design was considered for the trial but
decided against. The randomization built into the web-based
iQuit computer program is easily implemented, maintains
allocation concealment, and avoids selection bias. In addition,
if there is a clustering of outcomes, an individually randomized
design requires a smaller sample size to detect an effect. The
computer program randomizes participants during the initial
consultation. The allocation sequence is not accessible to
smoking cessation advisors or participants in advance, and the
advisors and participants remain blinded to group allocation
until after the first set of questions.
However, there are disadvantages to individual randomization
in trials of behavioral interventions. Participants may be
disappointed to learn that they will not be receiving the iQuit
intervention and feel they are not active participants in the trial.
This may, in part, be due to a lack of understanding of RCTs
and the purpose of control groups. Therefore, in the participant
information sheet and with smoking cessation advisors in
training, we provide an explanation of RCTs and why people
allocated to a control group are as important to research as the
group receiving the intervention. Advisors also reassure
participants they will still receive support from them during
their quit attempt.
However, there is the potential for this to lead to systematic
differences between intervention and control conditions in the
usual care component as smoking cessation advisors try to
compensate for this disappointment. However, participants not
receiving the intervention still have access to all available
resources in the same way as the group receiving the
intervention. Therefore, any additional support given to the
control arm would attenuate any intervention effect and thus
have a conservative effect on the results.
Recruitment
We encouraged GP practices to recruit opportunistically rather
than proactively. Although proactive invitation letters can act
as a prompt for participation, this approach was not very
successful during our pilot trial [32] and would likely be
insufficient to recruit the numbers we require. However,
opportunistic recruitment has some disadvantages: (1) more
time is needed to talk with potential participants about the study,
which in a busy general practice can be a challenge, and (2)
recruiting participants who have had to make a quick decision
about taking part in the study. We therefore encouraged GP
practices to hand out study information to patients attending
other consultations (eg, diabetes clinics) and in the waiting room
to maximize the time available for reading information and
coming to a decision. With increased use of electronic-cigarettes
[2], smokers seeking support from smoking cessation services
have fallen over recent years [6]. Therefore, recruitment was
monitored internally and various strategies used to encourage
practices to be more active in their recruitment. Quarterly
newsletters of study progression were produced, and regular
contact with smoking cessation advisors enabled us to work
with them to identify individual issues with recruitment. In the
majority of cases, the over-riding problem was a fall in numbers
seeking support through the surgery. Therefore, further GP
practices were recruited as necessary to ensure we maintained
a steady recruitment rate to reach our target.
Outcome Assessment
The preferred method for obtaining the initial response is by
text or email. Every attempt is made to obtain self-reported
smoking status in this way. However, where there has been no
response to initial attempts, participants are called instead. The
interviewer is initially blind to the participant’s group allocation;
however, during the course of the telephone interview, they will
become unblinded as details of the participants’ quit attempts
are discussed. Self-report outcomes, however, are naturally
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subject to bias in whichever way they are collected. We will
conform to the Russell Standard definitions of abstinence, and
a saliva sample will be obtained from all participants who
self-report a successful quit attempt to determine their smoking
status. This presents further disadvantages; for example, it may
yield a lower than expected response rate. However, attrition is
monitored along with recruitment, and decisions will be made
to compensate for a lower than anticipated return of saliva
samples. For example, early on during the trial, we decided to
increase the sample size to compensate for a lower than expected
return.
External Validity
In this trial, external validity is increased by using smoking
cessation advisors, employed by practices, rather than research
staff to deliver the intervention and the control intervention.
We used minimal inclusion and exclusion criteria for practices
and participants, and iQuit was designed to be easily
incorporated into usual care, whereas the text messages were
delivered independently of the practice. Opportunistic
recruitment also had the potential to include smokers who would
not necessarily have replied to a study intervention, thereby
increasing the diversity of the study population. However, there
still remains a limitation in the study design, as smokers with
a poor grasp of written English may struggle with the advice
report and texts.
Potential Benefits of the iQuit Program
If the iQuit program is demonstrated to be cost-effective, it
could be delivered across primary care in all regions. Over
100,000 smokers set a quit date in the NHS each year, of which
over 38,000 [45] are seen in primary care. It has the potential
to reach a large number of smokers seeking support to quit. It
may also be beneficial for smokers receiving cessation support
in other settings, such as a pharmacy, which treats over 20,000
smokers per year. The potential benefit would likely be highest
where less behavioral support is delivered.
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